All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How to treat patients with AL amyloidosis relapsing from Dara-CyBorD?

Dec 27, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in AL amyloidosis.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Morie Gertz, Mayo Clinic, Rochester, US. We asked, How to treat patients with amyloid light-chain (AL) amyloidosis relapsing from daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD)?

How to treat patients with AL amyloidosis relapsing from Dara-CyBorD?

Gertz opens by outlining the proportion of patients with AL amyloidosis who do not achieve a complete response following treatment with Dara-CyBorD. Gertz goes on to discuss the options available for these patients, including stem cell transplant, venetoclax in translocation (4;14)-positive patients, and pomalidomide, with special considerations for patients with cardiac involvement and close attention to dose modifications depending on response.